Intralesional application of recombinant human tumor necrosis factor alpha induces local tumor regression in patients with advanced malignancies.
Fourteen patients with different advanced solid tumors were treated by intratumoral application of recombinant human tumor necrosis factor alpha. In five patients, local tumor regression occurred. However, the duration of response was short, implying a rapid development of resistance to rTNF-alpha application. The main clinical side-effects, including chills, fever, anorexia and fatigue, were similar to systemic rTNF-alpha treatment. Cardiovascular, pulmonary or metabolic toxicities were not observed. This study demonstrates that a high concentration of rTNF-alpha at the tumor site has the potential to induce local tumor regressions and, therefore, seems more reasonable for further clinical investigations, especially in combination with other cytokines.
Bartsch
H H
HH
Department of Internal Medicine, University of Goettingen, F.R.G.
Pfizenmaier
K
K
Schroeder
M
M
Nagel
G A
GA
D000293:Adolescent; D000328:Adult; D000368:Aged; D018288:Carcinoma, Small Cell / Q000473:pathology; D002986:Clinical Trials as Topic; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007267:Injections; D008175:Lung Neoplasms / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
D014409:Tumor Necrosis Factor-alpha